Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $2,293,600.00 in Stock

Last updated on Wednesday, June 23, 2021 | 2021 MarketBeat

Twist Bioscience Co. (NASDAQ:TWST) insider William Banyai sold 20,000 shares of the stock in a transaction on Monday, June 21st. The stock was sold at an average price of $114.68, for a total transaction of $2,293,600.00. Following the transaction, the insider now directly owns 379,389 shares in the company, valued at $43,508,330.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Banyai also recently made the following trade(s):

  • On Friday, May 21st, William Banyai sold 20,275 shares of Twist Bioscience stock. The shares were sold at an average price of $96.06, for a total value of $1,947,616.50.
  • On Monday, April 26th, William Banyai sold 19,878 shares of Twist Bioscience stock. The shares were sold at an average price of $137.40, for a total value of $2,731,237.20.

Shares of NASDAQ:TWST traded up $1.35 during trading on Wednesday, reaching $120.14. The stock had a trading volume of 39,807 shares, compared to its average volume of 864,532. Twist Bioscience Co. has a 52 week low of $40.01 and a 52 week high of $214.07. The firm has a 50-day simple moving average of $112.66. The company has a market cap of $5.87 billion, a PE ratio of -44.92 and a beta of 0.72.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Thursday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.02). The firm had revenue of $31.20 million during the quarter, compared to the consensus estimate of $28.18 million. Twist Bioscience had a negative net margin of 109.15% and a negative return on equity of 25.47%. The business's revenue was up 61.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.85) EPS. On average, sell-side analysts anticipate that Twist Bioscience Co. will post -3.04 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC increased its holdings in shares of Twist Bioscience by 100.0% in the first quarter. International Assets Investment Management LLC now owns 200 shares of the company's stock valued at $26,000 after purchasing an additional 100 shares in the last quarter. Wealthcare Advisory Partners LLC acquired a new stake in shares of Twist Bioscience in the first quarter valued at approximately $27,000. Grant Street Asset Management Inc. acquired a new stake in shares of Twist Bioscience in the fourth quarter valued at approximately $45,000. Captrust Financial Advisors increased its holdings in shares of Twist Bioscience by 77.8% in the fourth quarter. Captrust Financial Advisors now owns 320 shares of the company's stock valued at $45,000 after purchasing an additional 140 shares in the last quarter. Finally, AdvisorNet Financial Inc acquired a new stake in Twist Bioscience during the 1st quarter worth $56,000. 95.03% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have commented on TWST shares. The Goldman Sachs Group started coverage on shares of Twist Bioscience in a research note on Friday, June 4th. They set a "neutral" rating and a $110.00 price target for the company. Piper Sandler started coverage on shares of Twist Bioscience in a research note on Monday, April 12th. They set an "overweight" rating and a $150.00 price target for the company. Finally, Zacks Investment Research upgraded shares of Twist Bioscience from a "sell" rating to a "hold" rating in a research note on Thursday, April 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. The company presently has an average rating of "Hold" and an average price target of $132.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

See Also: How does quantitative easing work?

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What is an Initial Public Offering (IPO)?

7 Semiconductor Stocks Set to Gain From the Chip Shortage

Who knew that something so tiny could create such a big problem? However, that’s the case with the semiconductor industry. Chip manufacturers are facing supply chain disruptions due to the Covid-19 pandemic.

Semiconductors are in high demand for the big tech companies who need the chips to power the servers for their data centers. But they are also needed for much of the technology we take for granted including laptops, tablets, mobile phones, gaming consoles, and automobiles – a sector that seems to be at the root of the current crisis.

Any weekend mechanic knows that even traditional internal combustion cars are heavily reliant on electronics. In fact, electronic parts and components account for 40% of a new, internal combustion vehicle. That’s more than doubled since 2000.

However as it turns out, some manufacturers may have overestimated how soon consumers would be ready for an “all-electric” future. And that meant that they didn’t forecast how much demand there would be for the kind of chips needed to do the mundane, but vital tasks of steering, braking, and even powering windows up and down.

Part of the problem is that U.S. businesses are heavily reliant on countries like China and Taiwan for their semiconductors. In fact, only about 12.5% of semiconductor manufacturing is done in the United States.

Of course, this creates a tremendous opportunity for the companies that manufacture these chips. And it comes at a good time. The semiconductor sector is notoriously cyclical and was coming down from the elevated demand for the 5G buildout.

In this special presentation, we’ll give you a list of seven semiconductor companies that you can invest in to take advantage of this opportunity.

View the "7 Semiconductor Stocks Set to Gain From the Chip Shortage".

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.